This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Ramipril

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221031

Version

6

Spl Product Data Elements

Ramipril Ramipril RAMIPRIL RAMIPRILAT FD&C RED NO. 40 FD&C YELLOW NO. 5 FD&C YELLOW NO. 6 GELATIN TITANIUM DIOXIDE STARCH, CORN FERROSOFERRIC OXIDE WHITE YELLOW CAPSULE ZA;43;1;25mg Ramipril Ramipril RAMIPRIL RAMIPRILAT D&C YELLOW NO. 10 FD&C RED NO. 40 GELATIN TITANIUM DIOXIDE STARCH, CORN FERROSOFERRIC OXIDE WHITE ORANGE CAPSULE ZA;44;2;5mg Ramipril Ramipril RAMIPRIL RAMIPRILAT FD&C BLUE NO. 1 FD&C RED NO. 40 FD&C YELLOW NO. 6 GELATIN TITANIUM DIOXIDE STARCH, CORN FERROSOFERRIC OXIDE WHITE RED CAPSULE ZA;45;5mg Ramipril Ramipril RAMIPRIL RAMIPRILAT D&C RED NO. 28 D&C YELLOW NO. 10 FD&C BLUE NO. 1 GELATIN TITANIUM DIOXIDE STARCH, CORN FERROSOFERRIC OXIDE WHITE BLUE CAPSULE ZA;46;10mg

Application Number

ANDA078832

Brand Name

Ramipril

Generic Name

Ramipril

Product Ndc

65841-658

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-655-06 in bottle of 30 Capsules Ramipril Capsules, 1.25 mg R x only 30 Capsules NDC 65841-656-01 in bottle of 100 Capsules Ramipril Capsules, 2.5 mg R x only 100 Capsules NDC 65841-657-01 in bottle of 100 Capsules Ramipril Capsules, 5 mg R x only 100 Capsules NDC 65841-658-01 in bottle of 100 Capsules Ramipril Capsules, 10 mg R x only 100 Capsules Ramipril Capsules, 1.25 mg Ramipril Capsules, 2.5 mg Ramipril Capsules, 5 mg Ramipril Capsules, 10 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.